Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 6/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12826128 | 0.90 | APLNR (0.37) | APLNRCNR2TAS2R14CNR1CA12 | |
| SCHEMBL12497941 | 0.90 | CNR2 (0.39) | APLNRCNR2TAS2R14TAAR1CNR1 | |
| SCHEMBL1462111 | 0.89 | APLNR (0.41) | APLNRCNR2TAS2R14CNR1CA12 | |
| SCHEMBL1492035 | 0.87 | APLNR (0.43) | APLNRCNR2TAS2R14TAAR1CNR1 | |
| SCHEMBL12497894 | 0.80 | APLNR (0.39) | APLNRCNR2TAS2R14CNR1NR3C1 | |
| SCHEMBL9930750 | 0.79 | CNR2 (0.42) | APLNRCNR2TAS2R14CNR1NR3C1 | |
| SCHEMBL1460926 | 0.79 | CNR2 (0.40) | APLNRCNR2TAS2R14CNR1CA12 | |
| SCHEMBL9930518 | 0.77 | CNR2 (0.42) | APLNRCNR2TAS2R14CNR1CA12 | |
| SCHEMBL1492094 | 0.77 | CNR2 (0.44) | APLNRCNR2TAS2R14CNR1NR3C1 | |
| SCHEMBL9930946 | 0.74 | ACHE (0.37) | CNR2CA2NR3C1ALDH1A1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | APLNR 4487/4885CNR2 4318/4885TAS2R14 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.